| Literature DB >> 17945008 |
Martine Maat1, Corinne M P Buysse, Marieke Emonts, Lodewijk Spanjaard, Koen F M Joosten, Ronald de Groot, Jan A Hazelzet.
Abstract
BACKGROUND: To gain insight into factors that might affect results of future case-control studies, we performed an analysis of children with sepsis and purpura admitted to the paediatric intensive care unit (PICU) of Erasmus MC-Sophia Children's Hospital (Rotterdam, The Netherlands).Entities:
Mesh:
Year: 2007 PMID: 17945008 PMCID: PMC2556765 DOI: 10.1186/cc6161
Source DB: PubMed Journal: Crit Care ISSN: 1364-8535 Impact factor: 9.097
Figure 1Distribution of age at admission in children with sepsis and purpura. The children are subdivided according to causative organism. N. meningitidis, Neisseria meningitidis. Not further defined (n.f.d.).
Comparison of disease characteristics between non-survivors and survivors
| Survivorsa | Non-survivorsa | |
| Total number of children (%) | 242 | 45 |
| (84.3) | (15.7) | |
| Male-to-female ratio | 1.1 | 1.7 |
| Number of children with DIC (%) | 174b | 32b |
| (75) | (97) | |
| B (%) | 147 (74.2) | 28 (73.7) |
| C (%) | 37 (18.7) | 7 (18.4) |
| PRISM score | 14c | 23c |
| (1 to 37) | (8 to 44) | |
| Predicted death rate (%)d | 3.1c | 87.4c |
| (0 to 100) | (1.1 to 100.0) | |
| Base excess (mmol/L) | -7c | -13c |
| (-23 to 4.4) | (-28 to 0.6) | |
| Lactate (mmol/L) | 3.7c | 6.6c |
| Geometric mean, 95% CI | 3.4 to 4.3 | 5.8 to 7.4 |
| C-reactive protein (mg/L) | 106c | 53c |
| (10 to 334) | (6 to 226) | |
| Fibrinogen (g/L) | 2.8c | 0.9c |
| (0.3 to 6.8) | (0.2 to 5.4) | |
| Platelet count (×103/μL) | 126c | 47c |
| (15 to 475) | (13 to 202) | |
| Leukocytes (×103/μL) | 10.6c | 4.7c |
| Geometric mean, 95% CI | 9.5 to 11.9 | 3.7 to 6.0 |
| Glucose (mmol/L) | 6.3c | 4.3c |
| Geometric mean, 95% CI | 5.9 to 6.8 | 3.6 to 5.3 |
aResults represent median (min-max) unless stated otherwise. bp < 0.01.cp < 0.001. dPredicted death rate was based on the Rotterdam score. CI, confidence interval; DIC, disseminated intravascular coagulation; PRISM, Paediatric Risk of Mortality.
Figure 2Case fatality rate (CFR) and CFR trend line during the study period.
Figure 3Distribution of age at admission among survivors and non-survivors of sepsis and purpura.
Figure 4Number of children with sepsis and purpura due to Neisseria meningitidis per year (since 1988), admitted to the paediatric intensive care unit of Erasmus MC-Sophia Children's Hospital (Rotterdam, The Netherlands).
Incidence of serogroup, serotype, and serosubtype of Neisseria meningitidis
| Serogroup | Serotype | Serosubtype | Number | Percentage |
| B | 1 | P1.4 | 4 | 1.8 |
| P1.16 | 4 | 1.8 | ||
| NT | 3 | 1.4 | ||
| Other | 1 | 0.5 | ||
| 2A | 3 | 1.4 | ||
| 4 | P1.4 | 57 | 26 | |
| P1.6 | 3 | 1.4 | ||
| P1.7 | 3 | 1.4 | ||
| P1.9 | 4 | 1.8 | ||
| P1.10 | 4 | 1.8 | ||
| P1.15 | 5 | 2.3 | ||
| NT | 28 | 12.8 | ||
| Other | 13 | 5.9 | ||
| NT | P1.1 | 6 | 2.7 | |
| P1.4 | 8 | 3.7 | ||
| NT | 8 | 3.7 | ||
| Other | 4 | 1.8 | ||
| Other | 17 | 7.8 | ||
| C | 2A | P1.2 | 12 | 5.5 |
| P1.5 | 9 | 4.1 | ||
| P1.7 | 1 | 0.5 | ||
| NT | 7 | 3.2 | ||
| 2B | P1.1 | 1 | 0.5 | |
| P1.2 | 7 | 3.2 | ||
| 4 | P1.4 | 3 | 1.4 | |
| NT | 2 | 0.9 | ||
| Other | 2 | 0.9 |
NT, non-typable.
Comparison of disease characteristics based on serogroup of Neisseria meningitidis
| Serogroup B | Serogroup C | |
| Total number of children | 175 | 44 |
| Age in years | 2.8b | 6.0b |
| (0.1 to 17.9) | (0.1 to 16.5) | |
| PRISM score | 16 | 14 |
| (1 to 37) | (1 to 35) | |
| Predicted death rate (%)c | 8.9 | 4.9 |
| (0 to 100) | (0 to 100) | |
| Number of children with DIC (%) | 128 | 32 |
| (81) | (74) | |
| Number of PICU-free days | 24 | 25 |
| (0 to 28) | (0 to 27) | |
| Base excess (mmol/L) | -8 | -8.0 |
| (-21 to 4.4) | (-28 to 3) | |
| Lactate (mmol/L) | 4.2 | 3.5 |
| Geometric mean, 95% CI | 3.8 to 4.6 | 2.9 to 4.2 |
| C-reactive protein (mg/L) | 82d | 128d |
| (6 to 287) | (20 to 326) | |
| Fibrinogen (g/L) | 2.4 | 2.8 |
| (0.2 to 6.8) | (0.3 to 6.6) | |
| Platelet count (×103/μL) | 110 | 113 |
| (15 to 475) | (13 to 336) | |
| Leukocytes (×103/μL) | 8.8e | 12.2e |
| Geometric mean, 95% CI | 7.6 to 10.1 | 9.9 to 15.0 |
| Glucose (mmol/L) | 5.9 | 6.2 |
| Geometric mean, 95% CI | 5.4 to 6.5 | 5.5 to 6.9 |
aResults represent median (min-max) unless stated otherwise. bp < 0.001. cPredicted death rate was based on the Rotterdam score. dp < 0.01. ep < 0.05. CI, confidence interval; DIC, disseminated intravascular coagulation; PICU, paediatric intensive care unit; PRISM, Paediatric Risk of Mortality.
Comparison of disease characteristics between children with sepsis and purpura before and after the national meningococcal C vaccination campaign (July 2002)
| Before meningococcal C vaccinationa | After meningococcal C vaccinationa | |
| Total number of children (%) | 248 | 39 |
| (86.4) | (13.6) | |
| Case fatality (%) | 45b | 0b |
| (18.1) | (0) | |
| Age in years | 3.2 | 2.5 |
| (0.1 to 17.9) | (0.3 to 13.1) | |
| Number of children with DIC (%) | 186c | 20c |
| (79.5) | (62.5) | |
| Number of PICU-free days | 24c | 25c |
| (0 to 28) | (0 to 27) | |
| PRISM score | 15 | 20 |
| (1 to 44) | (2 to 37) | |
| Predicted death rate (%)d | 5.6 | 8.1 |
| (0 to 100) | (0 to 100) | |
| Base excess (mmol/L) | -7.7 | -8 |
| (-28 to 4.4) | (-18 to -2) | |
| Lactate (mmol/L) | 4.1 | 4.0 |
| Geometric mean, 95% CI | 3.8 to 4.4 | 3.3 to 4.8 |
| C-reactive protein (mg/L) | 93 | 84 |
| (6 to 326) | (25 to 334) | |
| Fibrinogen (g/L) | 2.5 | 3.2 |
| (0.2 to 6.8) | (0.3 to 6.4) | |
| Platelet count (×103/μL) | 110 | 135 |
| (13 to 475) | (25 to 227) | |
| Leukocytes (×103/μL) | 8.9 | 12.1 |
| Geometric mean, 95% CI | 7.9 to 10.0 | 9.4 to 15.6 |
| Glucose (mmol/L) | 5.7c | 7.2c |
| Geometric mean, 95% CI | 5.3 to 6.2 | 6.2 to 8.2 |
aResults represent median (min-max) unless stated otherwise. bp < 0.01. cp < 0.05. dPredicted death rate was based on the Rotterdam score. CI, confidence interval; DIC, disseminated intravascular coagulation; PICU, paediatric intensive care unit; PRISM, Paediatric Risk of Mortality.
Figure 5Use of inotropic agents during the study period 1988 to 2006. Some patients received more than one inotropic agent. Therefore, the number of patients in this figure exceeds the number of patients in this study (N = 287).